<DOC>
	<DOCNO>NCT01439490</DOCNO>
	<brief_summary>Estrogens implicate development ovarian cancer estrogen receptor ( ER ) alpha beta present 20-100 % ovarian cancer patient . For reason , antihormonal therapy anti-estrogens ER-antagonists potentially attractive treatment option . However , small proportion patient ( 5-19 % ) respond antihormonal therapy . ER-expression ER-positive breast cancer assess positron emission tomography ( PET ) [ 18F ] fluoroestradiol ( FES ) . In study investigator evaluate whether FES-PET use visualize quantify ER-expression ovarian cancer . If result positive , would warrant exploration FES-PET imaging ovarian cancer .</brief_summary>
	<brief_title>FES-PET Determine ER-expression Epithelial Ovarian Cancer</brief_title>
	<detailed_description>Investigators evaluate whether FES-PET use visualize quantify ER-expression ovarian cancer . If result positive , would warrant exploration FES-PET imaging ovarian cancer .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<criteria>1 . Histological evidence high clinical suspicion epithelial ovarian cancer 2 . The presence least one measurable lesion ( RECIST version 1.1 ) . 3 . Histology cytology obtain ( may ascites ) 4 . Eastern Cooperative Oncology Group performance status 02 . 5 . Postmenopausal status ( define either &gt; 45 year amenorrhea &gt; 12 month , prior bilateral ovariectomy ) 6 . No history ERpositive malignancies 7 . Signed write informed consent 8 . Able comply protocol 1 . Use estrogen receptor ligand , include tamoxifen , fulvestrant estrogen , 5 week entry study 2 . Lifeexpectancy â‰¤ 3 month</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>